# A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

> **NCT01559363** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kadmon, a Sanofi Company** · enrollment: 69 (actual)

## Conditions studied

- Polycystic Kidney, Autosomal Dominant

## Interventions

- **DRUG:** Tesevatinib

## Key facts

- **NCT ID:** NCT01559363
- **Lead sponsor:** Kadmon, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-11
- **Primary completion:** 2019-02-08
- **Final completion:** 2019-02-08
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01559363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01559363, "A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01559363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*